Ionis Pharmaceuticals Drops Another After Phase 3 Setback
Ionis Pharmaceuticals dropped again after a Phase 3 failure in transthyretin amyloid cardiomyopathy, triggering a bro...
Flat index levels can mask underlying shifts among components; still, broader market movements may occur through price changes in parts.
28,641 articlesIonis Pharmaceuticals dropped again after a Phase 3 failure in transthyretin amyloid cardiomyopathy, triggering a bro...
Bitcoin climbs on geopolitical optimism, with traders betting on a swift de-escalation. The market sees a surge in se...
Traders are chasing the best stocks trade opportunities in a volatile February session. The focus is on highly liquid...
Institutional moves shape the AI stock landscape. This article dives into Philippe Laffont’s Coatue strategy, why Nvi...
Two durable energy bets stand out in 2026, blending a royalty based producer with a diversified energy fund to weathe...
As tariffs and a stronger dollar shape markets, IDV’s 4.7% yield just proved its income stream can endure, even as qu...
In March 2026, traders are weighing CenterPoint Securities alternatives as costs diverge and platforms upgrade featur...
Retirees may see smaller Social Security checks than expected due to overlooked rules. This report highlights three u...
Qualcomm is navigating a tough start to 2026. A memory crunch, potential shifts with Apple, and a large buyback are m...
QuantumScape faces a volatile path from lab breakthroughs to mass production. This guide breaks down what the stock d...
Amgen's dividend has powered income-focused portfolios for years, but regulatory and pricing challenges raise questio...
When regulators issue a move like government orders anthropic pull, the shockwaves reach crypto markets and risk mana...